Taking ADCs beyond oncology

Merck
& Co. Inc. partnered with Ambrx
Inc. because the pharma hopes to build upon the biotech's near-decade
of experience in site-specific peptide modification to move antibody-drug
conjugates beyond oncology.

Last month, Merck agreed to pay
Ambrx $15 million up front and up to $288 million in milestones to use this
technology to develop antibodies against an undisclosed number of pre-defined
targets. The deal marks Ambrx's third antibody partnership in three years.

72
words displayed of
1041
words total.

To read this article, you must be an Archives subscriber. Please choose one of the options below.

Read the Rest of this Article

Current Subscribers

Purchase This Article for Individual Use :

Access this BioCentury on BioBusiness article article for your individual use via a permanent link that allows you to read or print the article, and any sub-articles, charts, tables and/or graphs related to this specific story: $85.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article, including any sub-articles, charts, tables and/or graphs related to this specific article, with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $85 USDPurchase this article for limited one-time distribution and website posting $750 USD

Subscription Option

Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.

Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.

Free Trial 4 Weeks of Access

Get a 4-week free trial subscription to see the important articles you are missing.